Simplification to EVG-COBI-TAF-FTC plus Darunavir

Study 119
### Study Design: Study 119

**Background:** Open-label, randomized Phase 3 trial comparing simplification to EVG-COBI-TAF-FTC plus darunavir versus continuation of baseline salvage ART regimen containing darunavir

**Inclusion Criteria** \( n = 135 \)
- HIV RNA <50 copies/mL on DRV-containing regimen
- On regimen for ≥4 months
- At least 2 prior regimen failures and ≥2-class DRMs
- No DRV RAMs, no INSTI resistance, ≤3 TAMs, no Q151M or T69ins

**Treatment Arms**
- EVG-COBI-TAF-FTC + DRV (Switch group)
- Remain on baseline ART (No switch group)

*Abbreviations: RAM = resistance associated mutation, INSTI = integrase strand transfer inhibitor, TAM’s = thymidine analogue mutations*

Simplification to EVG-COBI-TAF-FTC plus DRV
Study 119: Design

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>EVG-COBI-TAF-FTC + DRV (N=89)</th>
<th>Baseline Regimen (N=46)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, years</td>
<td>49</td>
<td>47</td>
</tr>
<tr>
<td>Male</td>
<td>82</td>
<td>61</td>
</tr>
<tr>
<td>Black (or African descent)</td>
<td>39</td>
<td>57</td>
</tr>
<tr>
<td>Median CD4 count, cells/mL</td>
<td>519</td>
<td>518</td>
</tr>
<tr>
<td>Median eGFR, mL/min (Cockroft-Gault)</td>
<td>99</td>
<td>100</td>
</tr>
<tr>
<td>Median # pills per day in ART regimen</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>&gt;6 pills per day in ART regimen, %</td>
<td>40</td>
<td>37</td>
</tr>
<tr>
<td>At least BID dosing, %</td>
<td>65</td>
<td>65</td>
</tr>
<tr>
<td>Tenofovir, %</td>
<td>61</td>
<td>54</td>
</tr>
<tr>
<td>Raltegravir, %</td>
<td>56</td>
<td>50</td>
</tr>
<tr>
<td>2 class / 3 class resistance, %</td>
<td>70 / 26</td>
<td>74 / 20</td>
</tr>
<tr>
<td>M184V/I / K65R, %</td>
<td>85 / 20</td>
<td>78 / 30</td>
</tr>
<tr>
<td>NNRTI resistance / PI resistance</td>
<td>89 / 38</td>
<td>87 / 28</td>
</tr>
</tbody>
</table>

Simplification to EVG-COBI-TAF-FTC plus DRV

Study 119: Results

Week 24 and 48: Virologic Response (Full analysis set)

Simplification to EVG-COBI-TAF-FTC plus DRV
Study 119: Results

Week 24 and 48: Medication Adherence

Simplification to EVG-COBI-TAF-FTC plus DRV
Study 119: Result

Week 48: Urine Protein-to-Creatinine Ratios

**Tubular Proteinuria**

- **Proteinuria (UPCR)**
  - EVG-COBI-TAF-FTC + DRV: -27.0%
  - Baseline ART Regimens: -25.0%

- **RBP:Cr**
  - EVG-COBI-TAF-FTC + DRV: 14.0%
  - Baseline ART Regimens: 17.0%

- **β2M:Cr**
  - EVG-COBI-TAF-FTC + DRV: -29.0%
  - Baseline ART Regimens: 13.0%

RBP:Cr = retinol binding protein:creatinine ratio; β2M:Cr = beta-2 microalbumin:creatinine ratio

Conclusions: “This study demonstrated that regimen simplification from a 5-tablet regimen to the 2-tablet, once-daily combination of E/C/F/TAF plus DRV has durable maintenance of virologic suppression and improvements in specific markers of renal safety. Such a strategy may lead to greater adherence and improved quality of life.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*